In vitro-in vivo correlation of hepatobiliary drug clearance in humans.
about
Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretionMembrane transporters in drug developmentScaling and systems biology for integrating multiple organs-on-a-chip.In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport.Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytesInfluence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes.Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.In vitro and in vivo drug disposition of cilengitide in animals and human.Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Intestinal permeability and its relevance for absorption and elimination.In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations.On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytesPrediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation.Inhibition of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Regulates the Hepatobiliary Excretion and Plasma Exposure of Thienorphine and Its Glucuronide Conjugate.Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion.Human clearance prediction: shifting the paradigm.Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.The right compound in the right assay at the right time: an integrated discovery DMPK strategy.In vitro methods to support transporter evaluation in drug discovery and development.An evaluation of the latest in vitro tools for drug metabolism studies.Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes.Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance.Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes.Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.Structure-pharmacokinetic relationship of in vivo rat biliary excretion.Evaluation of hypothermia on the in vitro metabolism and binding and in vivo disposition of midazolam in rats.A novel matrix for the short-term storage of cells: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes.
P2860
Q28570070-648839FF-813E-492E-96F8-1E81F4E2BBA1Q29616802-C40C8E08-5999-4427-B05A-EF95EE565AA6Q30410626-8EDAE434-4880-4710-9F3F-0BB53497E0D3Q34211108-96FE0CFD-D69B-438B-9F94-3BC1A03C1366Q34330504-B54CCA61-E069-4E3D-B30A-0DE02C535FF8Q34990717-DE1E2058-A178-458D-8114-85D255581220Q35086229-8A52A277-D3E9-4355-9557-96AE8DCE50B3Q35086354-5CB32958-D55A-4989-8B17-CC658E4EBE7BQ35607383-2034983A-9CC8-4AB8-B2D9-AADC1AA6032EQ35967888-613CE5BD-66FF-4C5C-A00D-FF299A026CD4Q36719621-5F6A83E3-0B83-41AA-9564-45AC96BA0220Q36877307-3D5CC013-DF46-46B1-9EC4-FD3B3D5A544DQ36972804-9452EC4E-42CD-4FFB-A68E-85D586AD97FCQ36985043-2DD7796D-43CC-4208-8949-48D38357365DQ36985051-8BECA4BF-F3FB-47E5-BC4D-530CB9E1EE37Q36985094-CAFDD075-BEA2-409A-AA4D-7A13227A1766Q37103935-D519AD17-B8E8-408E-8815-105E25AD0AC3Q37139856-0514F675-68C1-4953-A57C-E4681A2E0E69Q37159255-688EFC29-E7B6-46C7-B4C4-A51B2D940CD3Q37188002-DCA226E4-01ED-4A83-9B3D-F6392D226336Q37554392-FA416339-4B03-4B72-84EA-210484AAFDCAQ37554400-308F0972-15E2-4335-8B31-ADED27E6A971Q37604385-4E07C90E-9BC8-4030-9507-30CEE2C89D67Q38014312-7C67E967-0126-46E1-8743-0F24A045ADF7Q38017309-F8674375-ABC0-499F-97EC-5000EABE4282Q38018653-80AA7396-2193-4B88-8345-FAAB16073A76Q38099194-749AE6F1-D2F0-415F-BB94-250F6D362D6FQ38160881-BA09C3E6-35BA-4AF7-BCB7-0129772B0764Q38626000-22F923D3-AF51-4C45-A49F-3C89BAF1BA9AQ39101424-16CB3C89-5423-4AE4-830F-817583C40F53Q39666574-39DEC0B2-49B4-4A94-8B9F-B15D84CB4A86Q40386706-7C332487-FF05-486C-B668-7034D84E41F3Q41812734-B2F1F386-43A5-4A21-99D8-A6A62C92E553Q41839207-49A63F9C-DB5D-42C0-AAE2-01F9C44E5D20Q42702351-96FAEE45-DA53-49F8-8C3A-3CD685155BAFQ42720364-57BEC797-820F-4028-BC0E-4D7AD13CB3F3Q42971222-7E9A36B2-83D8-4927-B750-7095EEE715F4Q46696627-0013223A-526B-430E-84BC-886CADB51B16Q47695110-91FAB812-22F5-4461-A8BC-306EC944FA02Q50795222-ADF171EB-9FF6-41A5-A75F-368D04DA8D35
P2860
In vitro-in vivo correlation of hepatobiliary drug clearance in humans.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vitro-in vivo correlation of hepatobiliary drug clearance in humans.
@en
type
label
In vitro-in vivo correlation of hepatobiliary drug clearance in humans.
@en
prefLabel
In vitro-in vivo correlation of hepatobiliary drug clearance in humans.
@en
P2093
P2860
P356
P1476
In vitro-in vivo correlation of hepatobiliary drug clearance in humans
@en
P2093
E M Leslie
G Ghibellini
L S Vasist
R J Kowalsky
W D Heizer
P2860
P304
P356
10.1038/SJ.CLPT.6100059
P407
P50
P577
2007-01-18T00:00:00Z